• Serotonin Inhibits HRP-Mediated Proximity Labeling: Mechanis

  2026-07-23

  This study uncovers a novel inhibitory effect of serotonin on horseradish peroxidase (HRP)-mediated proximity biotinylation using membrane-impermeant biotin-XX tyramide. The findings highlight the need to account for neurotransmitter interference in proximity labeling workflows and demonstrate a chemical strategy to reverse this inhibition, enhancing the reliability of proteomic mapping in the serotonin system.

• Bile Acid Metabolism Subtypes Mark Immune Dysfunction in CRC

  2026-07-23

  Feng et al. (2026) introduce a molecular subtyping of colorectal cancer (CRC) based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as markers of immune dysfunction and poor prognosis. Their integrative approach connects metabolic profiling with immune landscape characterization, offering new avenues for risk stratification and potential biomarker development in CRC.

• NADH in Mitochondrial Electron Transport Chain Research

  2026-07-22

  Harnessing reduced nicotinamide adenine dinucleotide (NADH) empowers precise control and measurement of cellular energy metabolism. Discover how APExBIO’s rigorously characterized NADH enables advanced workflows, high-throughput redox assays, and robust troubleshooting in mitochondrial and disease modeling research.

• Tirbanibulin Inhibits HPV Oncoproteins and Proliferation in

  2026-07-22

  This study demonstrates that tirbanibulin significantly downregulates key oncogenic proteins, including HPV E6 and E7, and inhibits cell proliferation in HPV-18–positive HeLa cells. The findings clarify tirbanibulin's molecular impact on cancer-related pathways, supporting further investigation in HPV-associated disease models.

• Blocking CaN/FoxO1/FABP4 Axis Reverses SERCA2-Induced Athero

  2026-07-21

  This study uncovers how SERCA2 dysfunction accelerates atherosclerosis through the calcineurin/FoxO1/FABP4 pathway, driving foam cell formation and lipid accumulation. Targeted inhibition of this axis, including blockade of FABP4, represents a mechanistic therapeutic strategy for mitigating vascular inflammation and plaque progression.

• Tioconazole (SKU B2051): Reliable Antifungal Solutions for L

  2026-07-21

  This article provides evidence-based guidance for biomedical researchers and laboratory scientists using Tioconazole (SKU B2051) in antifungal research. It addresses real-world challenges in experimental design, assay optimization, and product selection, demonstrating how Tioconazole’s validated purity and formulation support reproducible, high-sensitivity antifungal assays.

• LGK-974 (Porcupine Inhibitor): Dissecting Wnt Pathway Precis

  2026-07-20

  Explore the molecular precision of LGK-974, a leading PORCN inhibitor, as a tool for advanced interrogation of the Wnt signaling pathway. Discover unique insights into developmental biology and translational oncology that set this analysis apart.

• Apigenin: Translational Leverage for HDAC Inhibition in Onco

  2026-07-20

  Explore how Apigenin (5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one) unites mechanistic sophistication with translational relevance, spanning malignant mesothelioma growth inhibition to neuroprotection in Alzheimer’s disease. This thought-leadership piece delivers mechanistic rationale, evidence-based protocols, and strategic guidance for researchers seeking to leverage precision HDAC inhibition in both cancer and neurodegenerative models, with actionable insights unavailable on standard product pages.

• PRMT5 Inhibition Uncovers Glutamine Metabolism Vulnerability

  2026-07-19

  The referenced study demonstrates that MYCN-amplified neuroblastoma (MNA) cells are highly sensitive to PRMT5 inhibition, revealing a spliceosomal vulnerability that converges on disruptions in both epitranscriptomic regulation and glutamine metabolism. This mechanistic insight identifies new metabolic intervention points for high-risk pediatric neuroblastomas and informs the design of targeted cancer metabolism research strategies.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Dissecting Proteasome Inhibit

  2026-07-18

  Explore the advanced use of MG-262 (Z-Leu-Leu-Leu-B(OH)2) in unraveling skeletal muscle aging mechanisms. This article offers a unique, protocol-focused perspective on proteasome inhibition and its interplay with chaperone-mediated autophagy.

• CB-839 (Telaglenastat): Decoding Glutaminase 1 Inhibition fo

  2026-07-17

  Explore how CB-839 (Telaglenastat) advances cancer metabolism research by enabling precise, mechanistically informed glutaminolysis inhibition. This article delivers a deep dive into GLS1 targeting, integrating new epitranscriptomic insights and bridging assay design with translational relevance.

• Diclofenac in Intestinal Organoid Assays: Optimizing COX Inh

  2026-07-17

  Diclofenac, a high-purity non-selective COX inhibitor, is transforming inflammation and pharmacokinetic research within human iPSC-derived intestinal organoid models. This guide translates the latest breakthroughs into actionable protocols, troubleshooting strategies, and workflow enhancements for cutting-edge, human-relevant COX inhibition assays.

• HATU-Driven Peptide Synthesis Chemistry: Advanced Workflows

  2026-07-16

  Harnessing HATU for peptide synthesis chemistry unlocks rapid, high-yield amide and ester formation—even with challenging substrates—by leveraging its unique carboxylic acid activation mechanism. This guide translates recent research advances into actionable workflows and troubleshooting strategies, empowering researchers to streamline inhibitor development and expand chemical space.

• Berberrubine Modulates Urate Transporters and JAK2/STAT3 in

  2026-07-16

  The reference study demonstrates that berberrubine, a key metabolite of berberine, substantially mitigates hyperuricemia in mice by regulating urate transporters and suppressing the JAK2/STAT3 signaling pathway. These findings clarify critical mechanisms underlying renal protection and anti-inflammatory action, shaping future research into targeted therapies for hyperuricemia and related metabolic diseases.

• LncDACH1 Controls VSMC Phenotypic Switch in AVF Neointimal H

  2026-07-15

  This study uncovers LncRNA LncDACH1 as a key regulator of vascular smooth muscle cell (VSMC) phenotypic switching during neointimal hyperplasia (NIH), a major cause of arteriovenous fistula (AVF) failure in hemodialysis. By mapping the KLF9–LncDACH1–HSP90/SRPK1/AKT axis, the work provides mechanistic insight into AVF dysfunction and highlights potential molecular targets for therapeutic intervention.

16795 records 1/1120 page Next 12345 下5页 Last page